Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia

Philip D Harvey, Cynthia O. Siu, Antony D. Loebel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively. Treatment with flexible-dose lurasidone 40-160 mg/d, administered once daily in the evening, was associated with significantly reduced daytime sleepiness compared with flexibly dosed quetiapine XR 200-800 mg/d (p = 0.03, effect size = 0.36) at week 32 (month 6 of the continuation study endpoint). Incidence of markedly high sleepiness (ESS >. 10) was significantly higher in the quetiapine XR (200-800 mg/d) group compared with the lurasidone 40-160 mg/day both months 3 and 6 visits (p < 0.05). Lurasidone (40-160 mg/d) significantly improved neurocognitive performance compared to quetiapine XR (200-800 mg/d) before (effect size = 0.49) and after adjustment (effect size = 0.45) for sleepiness effect (p = 0.008 and 0.010, respectively). Increased daytime sleepiness was significantly associated with reduced neurocognitive performance (p = 0.019) and quality of well-being (p = 0.05). Our findings suggest that clinicians should actively monitor patients for the presence of daytime sleepiness due in part to its potential impact on neurocognitive performance and well-being.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalSchizophrenia Research: Cognition
Volume5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Double-Blind Method
Cognition
Schizophrenia
Social Adjustment
Randomized Controlled Trials
Placebos
Quality of Life
Lurasidone Hydrochloride
Quetiapine Fumarate
Incidence
Therapeutics

Keywords

  • Cognitive performance
  • Daytime sleepiness
  • Long-term double-blind study
  • Lurasidone
  • Quetiapine XR

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Psychiatry and Mental health

Cite this

@article{00aa566fe80f40029d9e2735cfe3b196,
title = "Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia",
abstract = "Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively. Treatment with flexible-dose lurasidone 40-160 mg/d, administered once daily in the evening, was associated with significantly reduced daytime sleepiness compared with flexibly dosed quetiapine XR 200-800 mg/d (p = 0.03, effect size = 0.36) at week 32 (month 6 of the continuation study endpoint). Incidence of markedly high sleepiness (ESS >. 10) was significantly higher in the quetiapine XR (200-800 mg/d) group compared with the lurasidone 40-160 mg/day both months 3 and 6 visits (p < 0.05). Lurasidone (40-160 mg/d) significantly improved neurocognitive performance compared to quetiapine XR (200-800 mg/d) before (effect size = 0.49) and after adjustment (effect size = 0.45) for sleepiness effect (p = 0.008 and 0.010, respectively). Increased daytime sleepiness was significantly associated with reduced neurocognitive performance (p = 0.019) and quality of well-being (p = 0.05). Our findings suggest that clinicians should actively monitor patients for the presence of daytime sleepiness due in part to its potential impact on neurocognitive performance and well-being.",
keywords = "Cognitive performance, Daytime sleepiness, Long-term double-blind study, Lurasidone, Quetiapine XR",
author = "Harvey, {Philip D} and Siu, {Cynthia O.} and Loebel, {Antony D.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.scog.2016.05.002",
language = "English (US)",
volume = "5",
pages = "7--12",
journal = "Schizophrenia Research: Cognition",
issn = "2215-0013",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia

AU - Harvey, Philip D

AU - Siu, Cynthia O.

AU - Loebel, Antony D.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively. Treatment with flexible-dose lurasidone 40-160 mg/d, administered once daily in the evening, was associated with significantly reduced daytime sleepiness compared with flexibly dosed quetiapine XR 200-800 mg/d (p = 0.03, effect size = 0.36) at week 32 (month 6 of the continuation study endpoint). Incidence of markedly high sleepiness (ESS >. 10) was significantly higher in the quetiapine XR (200-800 mg/d) group compared with the lurasidone 40-160 mg/day both months 3 and 6 visits (p < 0.05). Lurasidone (40-160 mg/d) significantly improved neurocognitive performance compared to quetiapine XR (200-800 mg/d) before (effect size = 0.49) and after adjustment (effect size = 0.45) for sleepiness effect (p = 0.008 and 0.010, respectively). Increased daytime sleepiness was significantly associated with reduced neurocognitive performance (p = 0.019) and quality of well-being (p = 0.05). Our findings suggest that clinicians should actively monitor patients for the presence of daytime sleepiness due in part to its potential impact on neurocognitive performance and well-being.

AB - Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR on daytime sleepiness and neurocognitive performance during a 6-month, double-blind continuation study, in subjects who completed an initial 6-week, randomized, placebo-controlled trial comparing these agents. Daytime sleepiness, cognitive performance, and health-related quality of life were assessed with the Epworth Sleepiness Scale (ESS), CogState computerized battery, and the Quality of Well-Being (QWB-SA) Scale, respectively. Treatment with flexible-dose lurasidone 40-160 mg/d, administered once daily in the evening, was associated with significantly reduced daytime sleepiness compared with flexibly dosed quetiapine XR 200-800 mg/d (p = 0.03, effect size = 0.36) at week 32 (month 6 of the continuation study endpoint). Incidence of markedly high sleepiness (ESS >. 10) was significantly higher in the quetiapine XR (200-800 mg/d) group compared with the lurasidone 40-160 mg/day both months 3 and 6 visits (p < 0.05). Lurasidone (40-160 mg/d) significantly improved neurocognitive performance compared to quetiapine XR (200-800 mg/d) before (effect size = 0.49) and after adjustment (effect size = 0.45) for sleepiness effect (p = 0.008 and 0.010, respectively). Increased daytime sleepiness was significantly associated with reduced neurocognitive performance (p = 0.019) and quality of well-being (p = 0.05). Our findings suggest that clinicians should actively monitor patients for the presence of daytime sleepiness due in part to its potential impact on neurocognitive performance and well-being.

KW - Cognitive performance

KW - Daytime sleepiness

KW - Long-term double-blind study

KW - Lurasidone

KW - Quetiapine XR

UR - http://www.scopus.com/inward/record.url?scp=84971378923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971378923&partnerID=8YFLogxK

U2 - 10.1016/j.scog.2016.05.002

DO - 10.1016/j.scog.2016.05.002

M3 - Article

AN - SCOPUS:84971378923

VL - 5

SP - 7

EP - 12

JO - Schizophrenia Research: Cognition

JF - Schizophrenia Research: Cognition

SN - 2215-0013

ER -